Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis
Objective
To describe our experience with aggressive outpatient transvaginal paracentesis to manage ovarian hyperstimulation syndrome (OHSS).
Design
Retrospective case series.
Setting
Private, academically affiliated IVF center.
Patient(s)
Women undergoing assisted reproductive technologies (ART) and having a diagnosis of OHSS.
Intervention(s)
Management of OHSS with hospitalization or outpatient transvaginal paracentesis between 1999 and 2007.
Main Outcome Measure(s)
Grade and stage of OHSS, need for hospitalization, and adverse events.
Result(s)
From 1999 to 2007, we identified 183 patients with OHSS. We began performing outpatient transvaginal paracentesis to treat OHSS in 2002. We have performed 146 outpatient transvaginal paracenteses in 96 patients with no procedure-related complications. With the implementation of early, aggressive, outpatient paracentesis, the number of patients requiring hospitalization for OHSS decreased. From 2006 to 2007, 29 patients were diagnosed with severe OHSS and 25 (86%) were managed as outpatients with transvaginal paracentesis with no complications.
Conclusion(s)
This report represents one of the largest series of patients with OHSS managed with outpatient transvaginal paracentesis. Although there continues to be a small percentage of patients with OHSS who require hospitalization, the vast majority of patients with severe OHSS at our center in the past 2 years had their condition successfully managed as outpatients with use of aggressive transvaginal paracentesis.
Key Words: Ovarian hyperstimulation syndrome, paracentesis
To access this article, please choose from the options below
L.P.S. has nothing to disclose. M.R.H. is a member of the Data Monitoring Committee for Bayer Healthcare Pharmaceuticals, Inc. M.M.A. is a consultant and lecturer for EMD Serono and for Organon, Inc., and performs research for Gene Security.
Accepted for poster presentation at the American Society for Reproductive Medicine Annual Meeting, San Francisco, California, November 8–12, 2008.
PII: S0015-0282(08)03894-6
doi:10.1016/j.fertnstert.2008.09.011
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

